Investor Overview Press Releases September 17, 2024 Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis September 10, 2024 Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference August 7, 2024 Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update View all » Events Sep 17, 20248:00 AM EDT 2024 Cantor Global Healthcare Conference Jun 11, 202411:20 AM EDT Goldman Sachs Global Healthcare Conference May 7, 20245:00 PM EDT Aclaris Therapeutics First Quarter 2024 Conference Call View all » Feature Presentation ITK Portfolio
September 17, 2024 Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
September 10, 2024 Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
August 7, 2024 Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update